Search Results - "CARDIOVASCULAR EVENTS"

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.

Authors: Deanfield, John Lincoff, A Michael Kahn, Steven E et al.

Source: Lancet. Nov2025, Vol. 406 Issue 10516, p2257-2268. 12p.

Subject Terms: SEMAGLUTIDE, MAJOR adverse cardiovascular events, CLINICAL trials, OBESITY, WEIGHT loss, WAIST circumference

Association of Handgrip Strength With Readmission, Mortality, and Exercise Capacity in Patients With Heart Failure.

Authors: Park, Soohyung Park, Se hyun Lee, Jieun et al.

Source: Journal of Aging & Physical Activity; Oct2025, Vol. 33 Issue 5, p506-516, 11p

Subject Terms: MORTALITY, RISK assessment, CARDIOPULMONARY fitness, PEARSON correlation (Statistics), RECEIVER operating characteristic curves, VENTRICULAR ejection fraction, PATIENT readmissions, MAJOR adverse cardiovascular events, MULTIPLE regression analysis, HEART failure, DESCRIPTIVE statistics, RETROSPECTIVE studies, MULTIVARIATE analysis, CARDIOPULMONARY system, LONGITUDINAL method, KAPLAN-Meier estimator, LOG-rank test, EXERCISE tolerance, MEDICAL records, ACQUISITION of data, EXERCISE tests, CONFIDENCE intervals, SURVIVAL analysis (Biometry), DATA analysis software, GRIP strength, CARDIAC rehabilitation, PROPORTIONAL hazards models, DISEASE risk factors

Geographic Terms: SOUTH Korea

Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.

Authors: Hakeem, Abdul Shah, Jehangir Ali Kumar, Rajesh et al.

Source: Journal of the American College of Cardiology (JACC). Dec2025, Vol. 86 Issue 23, p2330-2345. 16p.

Subject Terms: *TICAGRELOR, *MAJOR adverse cardiovascular events, *PERCUTANEOUS coronary intervention, *PLATELET aggregation inhibitors, *CLINICAL trials, *ST elevation myocardial infarction, *CLOPIDOGREL

Geographic Terms: PAKISTAN

Prognostic significance of angiography-derived index of microcirculatory resistance assessment after rotational atherectomy in patients with severely calcified lesions.

Authors: Sakamoto, Yuki Kawamori, Hiroyuki Toba, Takayoshi et al.

Source: Heart & Vessels. Dec2025, Vol. 40 Issue 12, p1079-1091. 13p.

Subject Terms: *MAJOR adverse cardiovascular events, *PERCUTANEOUS coronary intervention, *ATHERECTOMY, *DRUG-eluting stents, *ANGIOGRAPHY, *VASCULAR resistance, *CORONARY artery disease

Long-term prognostic value of the CT-derived fractional flow reserve combined with atherosclerotic burden in patients with non-obstructive coronary artery disease.

Authors: Wang, Zhiqiang Li, Zhennan Xu, Tingfeng et al.

Source: European Radiology. Dec2025, Vol. 35 Issue 12, p8068-8079. 12p.

Subject Terms: *MAJOR adverse cardiovascular events, *PREDICTION models, *ATHEROSCLEROTIC plaque, *RISK assessment, *PROGNOSIS, *DEEP learning, *COMPUTER-assisted image analysis (Medicine), *CORONARY occlusion

Association of Hypoxic Burden With Cardiovascular Events: A Risk Stratification Analysis of the Randomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea Cohort.

Authors: Peker, Yüksel Celik, Yeliz Zinchuk, Andrey et al.

Source: CHEST. Dec2025, Vol. 168 Issue 6, p1481-1493. 13p.

Subject Terms: *MAJOR adverse cardiovascular events, *HYPOXEMIA, *CARDIOLOGICAL manifestations of general diseases, *CONTINUOUS positive airway pressure, *DROWSINESS, *COHORT analysis, *SLEEP apnea syndromes, *RISK assessment

Letter to the Editor Regarding "Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases".

Authors: Salinas, Claudia A. Louder, Anthony Polinski, Jennifer et al.

Source: Rheumatology & Therapy. Dec2025, Vol. 12 Issue 6, p1187-1191. 5p.

Subject Terms: *BARICITINIB, *MAJOR adverse cardiovascular events, *INFECTION, *RHEUMATOID arthritis, *VENOUS thrombosis, *SCIENTIFIC observation, *SENSITIVITY analysis, *TREATMENT effectiveness

Association of Fasting Blood Sugar to High-density Lipoprotein Ratio with Short Term Outcome in Patients of Acute Coronary Syndrome: A Cohort Study.

Authors: MORAMPUDI, DONISRI SELVARAJ, SETHURAJ RAVEEKUMARAN, VIGNESSH et al.

Source: Journal of Clinical & Diagnostic Research. Dec2025, Vol. 19 Issue 12, p11-15. 5p.

Subject Terms: *ACUTE coronary syndrome, *MAJOR adverse cardiovascular events, *COHORT analysis, *PROGNOSIS, *HIGH density lipoproteins, *BLOOD sugar measurement, *PEOPLE with diabetes, CARDIOVASCULAR disease related mortality

Colchicine and cardiovascular events: An updated meta‐analysis of published randomized controlled trials.

Authors: Xie, Sining Galimberti, Federica Olmastroni, Elena et al.

Source: Journal of Internal Medicine. Dec2025, Vol. 298 Issue 6, p711-717. 7p.

Subject Terms: *COLCHICINE, *MAJOR adverse cardiovascular events, *AGGREGATION (Statistics), *CARDIOLOGICAL manifestations of general diseases, *TREATMENT effectiveness, *SECONDARY prevention, *RANDOMIZED controlled trials

Association of histologic and clinical activity with major adverse cardiovascular events in patients with inflammatory bowel disease: A cohort study.

Authors: Sun, Jiangwei Mårild, Karl Sundström, Johan et al.

Source: Journal of Internal Medicine. Dec2025, Vol. 298 Issue 6, p697-710. 14p.

Subject Terms: *MAJOR adverse cardiovascular events, *CARDIOVASCULAR diseases, *INFLAMMATION, *SYMPTOMS, *ULCERATIVE colitis, *INFLAMMATORY bowel diseases, *CROHN'S disease, *HAZARD function (Statistics)

Geographic Terms: SWEDEN

Comparative cardiovascular risk of sulfonylureas with low‐ and high‐affinities for cardiac mitochondrial adenosine triphosphate‐sensitive potassium channels versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A cohort study

Authors: Chen, Mei‐Hsiu Lin, Liang‐Yu Hung, Tung‐Ying et al.

Source: Diabetes, Obesity & Metabolism. Dec2025, Vol. 27 Issue 12, p7502-7513. 12p.

Subject Terms: *SULFONYLUREAS, *MAJOR adverse cardiovascular events, *TYPE 2 diabetes, *HYPOGLYCEMIC agents, *CARDIOVASCULAR diseases risk factors, *MORTALITY, *POTASSIUM channels, *SAFETY

Geographic Terms: TAIWAN

Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials.

Authors: Hasebe, Masashi Su, Chen‐Yang Keidai, Yamato et al.

Source: Diabetes, Obesity & Metabolism. Dec2025, Vol. 27 Issue 12, p7210-7220. 11p.

Subject Terms: *GLUCAGON-like peptide-1 agonists, *MAJOR adverse cardiovascular events, *TYPE 2 diabetes, *GLYCEMIC control, *CLINICAL trials, *CARDIOVASCULAR diseases risk factors, *MULTIPLE regression analysis

Inflammation and oxidative stress are associated with major adverse cardiovascular events in adults with preclinical hypertension.

Authors: Gimblet, Colin J. Kozlova, Dariya Wendt, Linder H. et al.

Source: Scientific Reports. 11/24/2025, Vol. 15 Issue 1, p1-9. 9p.

Subject Terms: *MAJOR adverse cardiovascular events, *INTERLEUKIN-6, *PREHYPERTENSION, *ADULTS, *BIOMARKERS, *INFLAMMATION, *OXIDATIVE stress, *CARDIOLOGICAL manifestations of general diseases

Prognostic value of lesion-specific and proximal coronary segment pericoronary adipose tissue CT Attenuation in ischemic heart disease with angina pectoris.

Authors: Wang, Lingli He, Wenfeng Jiang, Siyu et al.

Source: Scientific Reports. 11/24/2025, Vol. 15 Issue 1, p1-14. 14p.

Subject Terms: *ANGINA pectoris, *MAJOR adverse cardiovascular events, *CORONARY artery stenosis, *PROGNOSIS, *EPICARDIAL adipose tissue, *PREDICTION models, *MYOCARDIAL ischemia, *PROPORTIONAL hazards models

Clinical impact of an emergency fast-track pathway on early intervention and outcomes in acute coronary syndrome: a prospective cohort study.

Authors: Xiong, Wei Gao, Wei Zhou, Qibing et al.

Source: Scientific Reports. 11/24/2025, Vol. 15 Issue 1, p1-12. 12p.

Subject Terms: *ACUTE coronary syndrome, *MAJOR adverse cardiovascular events, *TREATMENT effectiveness, *EMERGENCY medical services, *COHORT analysis

Different eGFR markers and prediction of cardiovascular risk.

Authors: Tydén, Maria Batra, Gorav Fellström, Bengt et al.

Source: Journal of Internal Medicine. Nov2025, p1. 15p. 4 Illustrations.

Subject Terms: *MAJOR adverse cardiovascular events, *CYSTATIN C, *GLOMERULAR filtration rate, *CARDIOVASCULAR diseases risk factors, *CORONARY disease, *MORTALITY, *KIDNEY diseases, *BIOMARKERS

Association between the atherogenic index of plasma and major adverse cardiovascular events in individuals with metabolic syndrome: findings from the UK biobank.

Authors: Hu, Yuanjia Li, Wenlong Nie, Jingyuan et al.

Source: Cardiovascular Diabetology. 11/21/2025, Vol. 24 Issue 1, p1-14. 14p.

Subject Terms: *MAJOR adverse cardiovascular events, *METABOLIC syndrome, *BIOMARKERS, *LONGITUDINAL method, *AT-risk people, *CARDIOVASCULAR diseases, *BIOBANKS

Geographic Terms: UNITED Kingdom

Distinct immune-metabolic phenotypes underlie poor coronary collateral circulation.

Authors: Guo, Zi-Tong Lai, Hong-Mei Hu, Run-Xuan et al.

Source: Cardiovascular Diabetology. 11/18/2025, Vol. 24 Issue 1, p1-23. 23p.

Subject Terms: *CORONARY circulation, *MAJOR adverse cardiovascular events, *MACHINE learning, *PROTEOMICS, *THERAPEUTICS, *PHENOTYPIC plasticity

Clinical-genetic profiles and risk prediction model in childhood restrictive cardiomyopathy: a national cohort study of China.

Authors: Chen, Hao Wang, Shushui Quan, Junjun et al.

Source: BMC Medicine. 11/11/2025, Vol. 23 Issue 1, p1-11. 11p.

Subject Terms: *MAJOR adverse cardiovascular events, *PROGNOSTIC models, *CARDIOMYOPATHIES, *GENETIC mutation, *PEDIATRICS, *SYMPTOMS, *HEART transplantation

Geographic Terms: CHINA

Impact of sodium intake on blood pressure, mortality and major cardiovascular events: an umbrella review of systematic reviews and meta-analyses.

Authors: Yang, Qiuyu Vernooij, Robin W. M. Zhu, Hongfei et al.

Source: Critical Reviews in Food Science & Nutrition. 2025, Vol. 65 Issue 28, p5903-5913. 11p.

Subject Terms: *BLOOD pressure, *MAJOR adverse cardiovascular events, *THERAPEUTICS, *DIETARY sodium, *MORTALITY, *CARDIOVASCULAR diseases